| Bioactivity | LBA-3 is a selective, orally active inhibitor for sodium-coupled citrate transporter SLC13A5, with an IC50 of 67 nM. LBA-3 decreases levels of triglyceride and total cholesterol in oleic and palmitic acid (OPA)-stimulated AML12 cells, PCN-stimulated primary mouse hepatocytes and in mouse models, without detectable toxicity. LBA-3 is blood-brain barrier permeable[1]. |
| In Vivo | LBA-3 (50 mg/kg，口服，单剂量) 在 Sprague Dawley 大鼠中表现的药代动力学特征为血浆峰浓度 Cmax 为 288262.00 μg/L，AUC 为 704570.43 h/μg –1·L，口服生物利用度为 48.67%[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 2918263-09-7 |
| Formula | C18H18O5 |
| Molar Mass | 314.33 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang L, et al., Discovery of Highly Potent Solute Carrier 13 Member 5 (SLC13A5) Inhibitors for the Treatment of Hyperlipidemia. J Med Chem. 2024 Apr 25;67(8):6687-6704. |